A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)

A Multicenter Trial to Evaluate 18F-FDG Uptake by PET in Patients With Advanced Pancreatic Adenocarcinoma as an Early Indicator of Drug Activity

This study will determine whether [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.

Inclusion Criteria:

• Patient has a diagnosis of Stage IV pancreatic adenocarcinoma with distant metastases
• Patient is scheduled to receive standard chemotherapy containing gemcitabine
• Patient has not received prior systemic therapy for advanced pancreatic adenocarcinoma
• Patient must be available for periodic blood sampling, study-related assessments, and management at the treating institution

Exclusion Criteria:

• Patient has had open abdominal surgery within 6 weeks of the screening visit
• Patient has had radiotherapy to the thorax, abdomen, or pelvis within 6 months of the screening visit
• Patient has an active infection, inflammation, or unresolved bowel obstruction
• Patient has poorly controlled diabetes